Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Research Partnership’s MedTech Division appoints two Directors

Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

Webcast: Influencing HCP behaviours – Is now the perfect opportunity?

Putting behavioural science at the forefront of market research

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Webcast

Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights

CRYOPORT APPOINTS MIND+MATTER AS PART OF A GLOBAL BRAND DEVELOPMENT TENDER

Cryoport Inc has appointed creative communications agency Mind+Matter, an Ashfield Health company, part of UDG Healthcare as its strategic marketing partner to support the rebrand of the entire business alongside...

Ashfield Healthcare Communications rebrands as Ashfield Health

Ashfield Health, part of UDG Healthcare plc, announces transformational changes including the unveiling of a new Global President, a rebrand, and the launch of two new global agencies.

A MERGER THAT MATTERS

Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing relaunch as Mind+Matter     ‘First-in-class’ global agency conceived to confront the toughest challenges in healthcare and wellness   New global agency offers 24/7 access...

Webcast

The power of a good story: Turn your insights into effective storytelling with data visualisation

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)